Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.

Cost differential of immuno-oncology therapy delivered at community versus hospital clinics. Am J Manag Care. 2019 Mar 01;25(3):e66-e70 Authors: Gordan L, Blazer M, Saundankar V, Kazzaz D, Weidner S, Eaddy M Abstract OBJECTIVES: The site of cancer care delivery has been shown to be associated with the total cost of care. The magnitude of this effect in patients receiving expensive immuno-oncology (I-O) therapies has not been evaluated. We evaluated cost differentials between community-based and hospital-based outpatient clinics among patients receiving I-O therapies. STUDY DESIGN: This was a retrospective analysis utilizing Truven MarketScan Commercial and Supplemental Medicare claims databases. METHODS: Cost data for 3135 patients with non-small cell lung cancer, squamous cell carcinoma of the head and neck, bladder cancer, renal cell carcinoma, or melanoma who received pembrolizumab, nivolumab, and/or ipilimumab between January 1, 2015, and February 14, 2017, were analyzed as cost per patient per month (PPPM). Patients treated within a community setting were matched 2:1 with those treated at a hospital clinic based on cancer type, specific I-O therapy, receipt of radiation therapy, evidence of metastatic disease, gender, age, and evidence of surgery in the preindex period. RESULTS: Mean (SD) total (medical plus pharmacy) PPPM cost was significantly lower for patients treated in a community- versus hospital-based clinic ($22,685 [$16,205]...
Source: The American Journal of Managed Care - Category: Health Management Authors: Tags: Am J Manag Care Source Type: research

Related Links:

Authors: Cao M, Zhou M, Zhang J Abstract Patients with metastatic colorectal cancer (mCRC) beyond second line treatment have a poor prognosis. Regorafenib, TAS-102, fruquintinib, panitumumab and cetuximab are recommended single-agent chemotherapy regimens for patients exhibiting disease progression, this meta-analysis aimed to evaluate the efficacy and safety of these regimens in randomized controlled trials (RCTs). Eight RCTs with 3,832 cancer patients were included. Results showed that there was no significant difference in OS and PFS among the four drugs when comparing all patients or patients who have the KRAS ...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
CONCLUSION: The best of our knowledge it is the third description of brachial plexus schwannoma associated with breast cancer and the first with a synchronous association. The knowledge of this pathology and its potential to alter treatment justify the reporting of the present case. PMID: 32083563 [PubMed - as supplied by publisher]
Source: Breast Disease - Category: Cancer & Oncology Tags: Breast Dis Source Type: research
In this study, dosimeters were used to measure the testicular dose with and without testicular shielding to verify the effect of shielding. Anthropomorphic phantoms representing a human were used to estimate the doses absorbed in testicular and whole-body studies. The anthropomorphic phantom was irradiated according to the treatment protocol for colorectal cancer. Measurements were made using optically-stimulated luminescent dosimeters (OSLDs), composed of carbon-doped aluminum oxide, with characteristics suitable for radiotherapy dosimetry studies. A set of OSLDs was placed on a testicular phantom, attached to the lower e...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
Publication date: Available online 21 February 2020Source: Radiation Physics and ChemistryAuthor(s): Floriane Poignant, Hela Charfi, Chen-Hui Chan, Elise Dumont, David Loffreda, Étienne Testa, Benoit Gervais, Michaël BeuveAbstractThe use of gold nanoparticles to enhance radiation therapy efficiency has been thoroughly investigated over the past two decades. While theoretical studies have mostly focused on physical mechanisms and dose enhancement, studies of free radical production are scarce. In this work, we investigated the primary yield of free radicals (O•H and H2O2) induced by 20–90 keV monoen...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
Conclusion: Cytokine-induced killer cell immunotherapy combined with first-line chemotherapy could significantly improve the OS and PFS of patients with mCRC, particularly for patients with metastatic colon cancer. PMID: 32076550 [PubMed]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Immunology Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, T cells deficient in TRAF6 display enhanced T cell activation, CD28-indpendent stimulation and resistance to Treg cell-mediated suppression (176). Although TLR signaling can promote T cell resistance to Treg cells, the precise molecular mechanism remains yet to be elucidated. It is worth noting that TLR stimulation of T cells increases cytokine production (173, 177), thus future studies should delineate the effect of TLR-MyD88 signaling vs. subsequently induced cytokines in generating resistance to Treg cells. Lastly, it is also crucial to evaluate the effect of TLR signaling on regulatory T cells which also...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractOver the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develop resistance to these targeted therapies. Recently, immunotherapies such as immune checkpoint inhibitors have revolutionized the treatment paradigm for many types of malignancies. Immune checkpoint inhibitors have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, Hodgkin ’s lymphoma, bladder cancer and gastric cancer. However...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
The advent of immuno-oncology (IO) drugs profoundly changes our understanding of cancer biology as well as the management of patients at bedside. This is especially true for melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin's lymphoma or bladder cancer, for which these drugs already demonstrated substantial improvements in the patients' outcome. Beyond these indications, objective tumour responses have been reported in more than 20 different cancer types in early phase trials.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research
Dateline City: WILMINGTON, Del.&KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.&KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cance...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Head and Neck Cancer | Health Management | Kidney Cancer | Lung Cancer | Managed Care | Medicare | Melanoma | Non-Small Cell Lung Cancer | Radiation Therapy | Renal Cell Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Study | Yervoy